Weekly Recap

NeurologyLive Weekly Recap

Each week on Saturday morning, the NeurologyLive^® team puts together a weekly recap that offers a quick look into some of the top headlines in neurology news that you may have missed.

Ocrelizumab Reduces Thalamic Volume Loss, Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences

Ocrelizumab Reduces Thalamic Volume Loss, Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences

NeurologyLive® Staff

Neurology News Network for the week ending July 2, 2022. [WATCH TIME: 4 minutes]

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

NeurologyLive® Staff

Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]

Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis

Erenumab Outperforms Topiramate in PROs, Atogepant Dose-Dependent With Weight Changes, Vutrisiran FDA-Approved for ATTR Amyloidosis

NeurologyLive® Staff

Neurology News Network for the week ending June 18, 2022. [WATCH TIME: 3 minutes]

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

NeurologyLive® Staff

Neurology News Network for the week ending June 11, 2022. [WATCH TIME: 3 minutes]

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

NeurologyLive® Staff

Neurology News Network for the week ending May 28, 2022.

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

NeurologyLive® Staff

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

NeurologyLive® Staff

Neurology News Network for the week ending May 14, 2022. [WATCH TIME: 4 minutes]

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

NeurologyLive® Staff

Neurology News Network for the week ending May 7, 2022. [WATCH TIME: 4 minutes]

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

NeurologyLive® Staff

April 30th 2022

Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

NeurologyLive® Staff

April 23rd 2022

Neurology News Network for the week ending April 23, 2022. [WATCH TIME: 3 minutes]

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

NeurologyLive® Staff

April 16th 2022

Neurology News Network for the week ending April 16, 2022 [WATCH TIME: 3 minutes]

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

NeurologyLive® Staff

Neurology News Network for the week ending April 9, 2022. [WATCH TIME: 4 minutes]

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

NeurologyLive® Staff

Neurology News Network for the week ending April 2, 2022. [WATCH TIME: 3 minutes]

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

March 26th 2022

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

NeurologyLive® Staff

March 19th 2022

Neurology News Network for the week ending March 19, 2022.

Cladribine Shows No Increased COVID-19 Risks, Migraine Preventative Preferences, Benefits of Mobile Stroke Units

Cladribine Shows No Increased COVID-19 Risks, Migraine Preventative Preferences, Benefits of Mobile Stroke Units

NeurologyLive® Staff

March 12th 2022

Neurology News Network for the week ending March 12, 2022. [WATCH TIME: 4 minutes]

RapidAI Detects ICH With High Accuracy, Fenfluramine Plasma Levels Low, Nerivio More Effective With Behavioral Intervention

RapidAI Detects ICH With High Accuracy, Fenfluramine Plasma Levels Low, Nerivio More Effective With Behavioral Intervention

NeurologyLive® Staff

February 26th 2022

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

Carbidopa Levodopa Fractional Tablet Launched, Tenecteplase Shows Benefit After 24-Hour Window, Biogen Issues Response to CMS on Aducanumab

Carbidopa Levodopa Fractional Tablet Launched, Tenecteplase Shows Benefit After 24-Hour Window, Biogen Issues Response to CMS on Aducanumab

NeurologyLive® Staff

February 19th 2022

Neurology News Network for the week ending February 19, 2022. [WATCH TIME: 3 minutes]

Non-Whites Underrepresented in MS DMT Trials, Stroke Risk in PD-Related Genes, Phase 2a ADv Study Initiated

Non-Whites Underrepresented in MS DMT Trials, Stroke Risk in PD-Related Genes, Phase 2a ADv Study Initiated

NeurologyLive® Staff

February 12th 2022

Neurology News Network for the week ending February 12, 2022. [WATCH TIME: 3 minutes]

Optimal Teneceplase Dosing for Elders Identified, BMI Associated With Worse Cognitive Decline, Slight Improvements in Migraine Preventive Use

Optimal Teneceplase Dosing for Elders Identified, BMI Associated With Worse Cognitive Decline, Slight Improvements in Migraine Preventive Use

NeurologyLive® Staff

February 5th 2022

Neurology News Network for the week ending February 5, 2022. [WATCH TIME: 4 minutes]

CPAP Not Suggested for Elders, sNDA Accepted for Risdiplam in Presymptomatic SMA, Phase 2 Trial of GV-971 Gets Greenlight

CPAP Not Suggested for Elders, sNDA Accepted for Risdiplam in Presymptomatic SMA, Phase 2 Trial of GV-971 Gets Greenlight

NeurologyLive® Staff

January 29th 2022

Neurology News Network for the week ending January 29, 2022.

YTX-7739 Trials Suspended, ENSURE-2 Study of IMU-838 Initiated, Behavioral Involvement of FTD in ALS

YTX-7739 Trials Suspended, ENSURE-2 Study of IMU-838 Initiated, Behavioral Involvement of FTD in ALS

NeurologyLive® Staff

January 22nd 2022

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

MAO-B Inhibitors Underused in PD, CMS Proposes Decision on Aducanumab Coverage, PREMIUM II Trial of gammaCore Published

MAO-B Inhibitors Underused in PD, CMS Proposes Decision on Aducanumab Coverage, PREMIUM II Trial of gammaCore Published

NeurologyLive® Staff

January 15th 2022

Neurology News Network for the week ending January 15, 2022. [WATCH TIME: 4 minutes]

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

NeurologyLive® Staff

January 8th 2022

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Neurology News Network: Top FDA Approvals of 2021

Neurology News Network: Top FDA Approvals of 2021

NeurologyLive® Staff

January 1st 2022

Neurology News Network for the week ending January 1, 2022. [WATCH TIME: 4 minutes]

Aducanumab Cost Cut, REFINE-ALS Details Announced, NMOSD Shows Brighter Spotty Lesions Than MOGAD

Aducanumab Cost Cut, REFINE-ALS Details Announced, NMOSD Shows Brighter Spotty Lesions Than MOGAD

December 25th 2021

Neurology News Network for the week ending December 25, 2021.

BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance

BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance

NeurologyLive® Staff

December 18th 2021

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

$Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients$

Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients

NeurologyLive® Staff

December 11th 2021

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS

Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS

NeurologyLive® Staff

December 4th 2021

Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]

ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia

ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia

NeurologyLive® Staff

November 27th 2021

Neurology News Network for the week ending November 27, 2021.

<1 2 3 4 5 6 7 8 9 10 >

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.